Harmony Biosciences Holdings Inc. (NASDAQ:HRMY) is one of the most undervalued small-cap stocks to buy according to analysts. On June 11, Harmony Biosciences Holdings presented promising preclinical pharmacological data for BP1.15205, which is an investigational orexin 2 receptor (OX2R) agonist, at the 39th Annual Meeting of the Associated Professional Sleep Societies/APSS “SLEEP” in Seattle.
The data showed significant wake-promoting and cataplexy-suppressing effects in a standard transgenic mouse model of narcolepsy type 1. Narcolepsy is a chronic neurological disease affecting ~170,000 Americans, primarily characterized by excessive daytime sleepiness/EDS and cataplexy, along with other manifestations of REM sleep dysregulation.
A close-up of a pharmaceutical drug bottle, showcasing the potential of the company’s innovative therapies.
The disease is often caused by the loss of hypocretin/orexin, a neuropeptide crucial for sleep-wake stability. BP1.15205 features a new and unique chemical scaffold optimized for high potency, which showed statistically significant wake-promoting effects at very low oral doses in the transgenic mouse model. These findings support dosing flexibility to potentially treat all 3 central disorders of hypersomnolence at low doses, which could offer an optimized benefit-risk profile.
Harmony Biosciences Holdings Inc. is a commercial-stage pharmaceutical company that develops & commercializes therapies for patients with rare & other neurological diseases in the US.
READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.
This article is originally published at Insider Monkey.
